Aligos Therapeutics

As we gather to celebrate this season of gratitude, we want to extend our heartfelt appreciation to our incredible team at Aligos and everyone who supports our mission. Your dedication and passion propel our work forward every day.    Happy #Thanksgiving from Aligos! 

#ICYMI Last week at The Liver Meeting hosted by American Association for the Study of Liver Diseases (AASLD), our team presented data from multiple abstracts on our chronic #HepatitisB (CHB) and #MASH programs. Check out these photos from Dr. Rohit Loomba’s presentation of our HERALD Phase 2a study evaluating ALG-055009 for the treatment of #MASH at the conference!    #TLM24 #AASLD 

https://lnkd.in/djDeAXe2 #JMEDCHEM

I am very pleased to announce that our manuscript on the discovery of ALG-000184 was just published in the Journal of Medicinal Chemistry. This work represents the first public disclosure of the structure of ALG-000184.   ALG-000184 is a highly soluble and bioavailable prodrug of the potent capsid assembly modulator ALG-001075 and is advancing through Phase 1b studies with the Phase 2 protocol expected to be filed in Q1 2025.   Here is a link to the manuscript: https://lnkd.in/gewH8Z8G  

Today, we are pleased to announce positive data presented at American Association for the Study of Liver Diseases (AASLD)'s The Liver Meeting 2024, further highlighting the best-in-class potential of our innovative treatments for liver diseases.    Data presented on ALG-000184 continues to demonstrate potent antiviral activity for chronic #HepatitisB (CHB) in both HBeAg-positive and HBeAg-negative patients.   The data from our HERALD Phase 2a study highlighted the best-in-class potential of ALG-055009, a THR-β agonist, for the treatment of #MASH. Data presented includes an important subgroup analysis that showed that 11/14 subjects on a stable GLP-1 agonist treated with ALG-055009 had liver fat decreases, while 4/4 subjects treated with placebo had liver fat increases over the 12-week dosing period.     Read the full press release here: https://lnkd.in/ea3R6zbn    To learn more and view the presentations, visit the Scientific Presentations & Conferences page on the Aligos website at www.aligos.com. #TLM24 #AASLD

We’re taking a significant step forward in the fight against chronic #HepatitisB (CHB), as featured in Liver Disease News. The FDA has approved our IND application for ALG-000184, an oral treatment candidate for CHB, and we’re thrilled to progress this compound as we work towards a Phase 2 filing in Q1 2025.    Read more here:  https://lnkd.in/ecWUHNgx

Today we reported our Q3 2024 business progress and financial results, including updates on our chronic #HepatitisB, #MASH and pan-coronavirus programs.      For a detailed overview, read the full press release here: https://lnkd.in/egZxJc_J

This week, members of our team will deliver a poster presentation on ALG-093940, our potent and orally bioavailable small molecule PD-L1 inhibitor, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.     For those attending #SITC in person, join us on Friday, November 8, as we dive into the potential utility of our #PDL1 in addressing both chronic #HepatitisB (CHB) and #oncology, areas where innovative therapies are urgently needed.     #SITC2024 

#DidYouKnow that MASH is the leading cause of liver-related morbidity and can cause fibrosis and scarring which can lead to cirrhosis? Currently, there is only one therapy approved for the treatment of MASH which underlines the urgent unmet need for additional treatment options for these patients. At Aligos, we are developing ALG-055009, a THR-β agonist, as a potential best-in-class #MASH treatment. Learn more about our approach to advancing patient care (bit.ly/3A9M1Tv) and check out this article by The New York Times for a deeper look into the rising impact of MASH: bit.ly/3YGvw9R #LiverAwarenessMonth #LiverDisease

As we observe #LiverAwarenessMonth, it’s essential to highlight the growing prevalence of liver diseases, including hepatitis B virus (#HBV). With rates of chronic #HepatitisB (CHB) continuing to rise globally and the associated mortality rate, there is an urgent need for safe and effective treatments that can improve patient outcomes and quality of life.    Learn more about the symptoms and complications of HBV: